Spexis AG
SIX:SPEX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
BYC Co Ltd
KRX:001460
|
KR |
|
O
|
Otomo Logistics Service Co Ltd
TSE:9149
|
JP |
|
S
|
Skycity Entertainment Group Ltd
ASX:SKC
|
NZ |
|
C
|
Crompton Greaves Consumer Electricals Ltd
NSE:CROMPTON
|
IN |
|
ChangYuan Technology Group Ltd
SSE:600525
|
CN |
|
S
|
Shimano Inc
OTC:SMNNY
|
JP |
|
H
|
Hallmark Financial Services Inc
XBER:SSB
|
US |
|
M
|
Macmic Science & Technology Co Ltd
SSE:688711
|
CN |
Spexis AG
Total Liabilities
Spexis AG
Total Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Spexis AG
SIX:SPEX
|
Total Liabilities
CHf19.5m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
N/A
|
|
|
CRISPR Therapeutics AG
NASDAQ:CRSP
|
Total Liabilities
$343.4m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
16%
|
CAGR 10-Years
11%
|
|
|
Basilea Pharmaceutica AG
SIX:BSLN
|
Total Liabilities
CHf154.1m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-9%
|
|
|
Idorsia Ltd
SIX:IDIA
|
Total Liabilities
CHf1.6B
|
CAGR 3-Years
1%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Kuros Biosciences AG
SIX:KURN
|
Total Liabilities
CHf49.4m
|
CAGR 3-Years
52%
|
CAGR 5-Years
38%
|
CAGR 10-Years
N/A
|
|
|
Relief Therapeutics Holding SA
SIX:RLF
|
Total Liabilities
CHf15.4m
|
CAGR 3-Years
-37%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
Spexis AG
Glance View
Spexis Ltd. is clinical stage biopharmaceutical company, which engages in the research and development of macrocycle drugs. The company is headquartered in Allschwil, Basel-Landschaft. The company went IPO on 2018-05-15. The firm focuses on the discovery and development of first-in-class molecules in oncology and antimicrobial resistance leveraging its macrocyclic peptide technology platform. The firm's medicines pipeline includes Balixafortide (POL6326), which is in a Phase III trial in combination with eribulin in patients with advanced breast cancer; Outer Membrane Protein Targeting Antibiotics (OMPTA), which is an inhaled formulation of murepavadin for the treatment of Pseudomonas aeruginosa infections in patients with cystic fibrosis caused by Gram-negative bacteria; POL6014, which is an inhaled inhibitor of neutrophil elastase for the treatment of Cystic Fibrosis and other severe lung diseases, as well as Murepavadin (POL7080), which is an antibiotic with a mode of action to treat pseudomonas infections.
See Also
What is Spexis AG's Total Liabilities?
Total Liabilities
19.5m
CHF
Based on the financial report for Dec 31, 2023, Spexis AG's Total Liabilities amounts to 19.5m CHF.
What is Spexis AG's Total Liabilities growth rate?
Total Liabilities CAGR 5Y
-4%
Over the last year, the Total Liabilities growth was 85%. The average annual Total Liabilities growth rates for Spexis AG have been -16% over the past three years , -4% over the past five years .
